All News

COVID Test Antibody

NEJM: Early Combo Monoclonal Antibody Therapy in COVID-19

d Jack Cush, MD

NEJM has published the interim analysis of the REGN-COV2 trial, wherein an antibody cocktail reduced viral loads with less clinical consequences. 

Read Article
COVID infection mask

Combo Anti-Spike Protein Antibody for Mild to Moderate COVID-19

d Jack Cush, MD

JAMA has published the BLAZE-1 study, showing significant SARS-CoV-2 viral load reduction at day 11 and less COVID-19 progression when combination anti-spike monoclonal antibody therapy (bamlanivimab and etesevimab) was given to mild to moderate, non-hospitalized COVID-19 patients.

Read Article
QD Clinic - Smoking and RA: The dastardly, nastardly facts of smoking and RA https://t.co/H4jeFIXeGq https://t.co/xWxjzGZWQq

Links:

Dr. John Cush RheumNow ( View Tweet)
In the UK, NICE has recommending ed (to NHS) that filgotinib (Jyseleca) be approved for use in moderate to severe active rheumatoid arthritis (RA).https://t.co/g5zLwIa3MK

Links:

Dr. John Cush RheumNow ( View Tweet)

Don’t hold Benlysta for the COVID19 vaccine! Previous studies have shown that SLE pts on Benlysta (belimumab) still have good antibody response to vaccinations (including Prevnar14, PPSV23, flu and tetanus vaccines). ⁦@RheumNow⁩ https://t.co/4rFdcIKjkT

Links:

k dao KDAO2011 ( View Tweet)

Canadian lupus cohort of 560 SLE pts without myositis at baseline. Over time, only 5 pts developed myositis (after mean 8.5 yrs). Incidence = 1.05 per 1000 PYs. Arthritis, Raynauds, -Sm Abs were common, but only non-Whites had increased risk of myositis. https://t.co/fzWhUADjMz

Links:

Dr. John Cush RheumNow ( View Tweet)

NEW QD Clinic Differential Dx Myalgias & Arthralgias https://t.co/ozawoe6RMO

Links:

Dr. John Cush RheumNow ( View Tweet)

Denosumab inhibiting osteolysis? 22 pts undergoing revision THR surgery for osteolysis, 10 Rx w/ denosumab had 83% fewer osteoclasts @ osteolysis membrane–bone interface. Proof concept: DEN may have osteoclast effects at implant interface https://t.co/dJ06rk0SR3

Links:

Dr. John Cush RheumNow ( View Tweet)

Ehlers-Danlos Syndrome pts have higher association with GI conditions (IBS, etc OR =3.57), POTS & Autonomic dysfunction (OR=4.4), food allergy (OR= 3.9), CV complications (OR 6.1; MV dx, aortic aneurysm), longer hospitalizations (OR= 1.76) https://t.co/noobvrx0cQ

Links:

Dr. John Cush RheumNow ( View Tweet)

Though provoking piece by Dr. Len Calabrese in Healio,He references Drs. Schett and Scher writing in Nature Reviews Rheumatology on KOLs. Both articles are about reflection on what we do, how we do it, what motivates us. Good Reads https://t.co/HDlFRVJq1a https://t.co/CtqqiZuxwo

Links:

Dr. John Cush RheumNow ( View Tweet)

Swedish Armed Forces study suggests the least fit are at greatest risk for developing psoriasis later inlife. From 1968 -2005 1,886,542 military recruits were followed mean 31 yrs. Low CV fitness showed higher rate of psoriasis (HR 1.35) and PsA (HR 1.44) https://t.co/52zTjMM24y

Links:

Dr. John Cush RheumNow ( View Tweet)

Factors Predictive of SLE Flare After HCQ Taper/Discontinuation The benefits of hydroxychloroquine in lupus are many, but what if you were to withdraw HCQ? Read more: https://t.co/r5iDXBEuQP https://t.co/LImqA9y8Dn

Links:

Dr. John Cush RheumNow ( View Tweet)
Epidemiologic study of #SLE from CDC & lupus registries estimates there are 204,295 SLE pts in USA (2018). Prevalence=72.8 SLE/100,000 and is 9 X higher in females than males (129 vs 14.6/100,000), especially among Ame Indians/Alaska Natives, Black females https://t.co/5yHVQ9UqZ4

Links:

Dr. John Cush RheumNow ( View Tweet)

My note to the FDA staff: https://t.co/n2Pr2Kzrre
Dr. Janet Woodcock DrWoodcockFDA ( View Tweet)
Toci led to poorer outcomes in this study. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ https://t.co/95zaq2CEUU

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)

UTSW Rheum Grand Rounds - IgG4 Dz - Plasmablasts may be a useful biomarker; but is not generally available in clinical labs (must be done on fresh whole blood) @UTSWIMchief https://t.co/GlEKw0KD3O
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - IgG4 Dz common lab findings: hypergammaglobulinemia is common but elevated ESR/CRP are not. Most have elevated IgG4 serum levels @UTSWIMchief https://t.co/wR5FEqZTsX
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - IgG4 Dz commonly presents as major salivary and lacrimal gland enlargement, orbital disease, autoimmune pancreatitis, retroperitoneal (mass) fibrosis or tubulointerstitial nephritis. @UTSWIMchief

Dr. John Cush RheumNow ( View Tweet)

UTSW Rheum Grand Rounds - IgG4 Dz renal involvement; most common is tubulointerstitial nephritis @UTSWIMchief https://t.co/q8dZbgmvfK
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - Dr. Andres Quiceno on "IgG4 related Disease" Histologic criteria req >40% on IgG4/IgG cells @UTSWIMchief https://t.co/2kOioCdFiM
Dr. John Cush RheumNow ( View Tweet)
×